What Makes ProKidney Corp. (PROK) So Attractive [Yahoo! Finance]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company provided updates on its clinical progress and strategic priorities for advancing rilparencel through regulatory pathways. yezry/Shutterstock.com Chief Executive Officer Bruce Culleton stated that 2025 had been an important year for the company, marked by the positive Phase 2 study for REGEN-007, alignment with the FDA on the accelerated approval pathway for rilparencel, and robust enrollment for the Phase 3 PROACT 1 study. The company is well-positioned to achieve upcoming key milestones, including the completion of the enrolment for the Phase 3 PROACT 1 study this year and the pivotal eGFR slope data from the study in the second quarter of 2027. Culleton stated: “Our mission remains highly focused on bringing a potential new treatment option to patients with advanced CKD and diabetes at high risk of kidney failure – an area of high unme
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney (PROK) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PROK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong sell" tMarketBeat
- ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerGlobeNewswire
- ProKidney (PROK) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PROK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "seMarketBeat
- ProKidney (PROK) was upgraded by Jefferies Financial Group Inc. to "strong-buy".MarketBeat
- ProKidney GAAP EPS of -$0.52 beats by $0.18, revenue of $0.89M beats by $0.35M [Seeking Alpha]Seeking Alpha
PROK
Earnings
- 3/18/26 - Miss
PROK
Sec Filings
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form ARS
- 4/17/26 - Form DEF
- PROK's page on the SEC website